NCT05953350
A Phase Ib/II Study Confirmed Inhibition of Autophagy Synergizes Anti-tumor Effect of High Dose CDK4/6i
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
Version history last read from ClinicalTrials.gov on Aug 31, 2026. The record was updated there on Nov 20, 2026; versions filed since then are not listed here yet.
All 3 versions: 3 with changes below. See every version on ClinicalTrials.gov ↗
- Minor Trial completed
- Notable Start date: Jun 12, 2023 to Nov 7, 2023
- Primary completion date changed from estimate of Dec 31, 2023 to May 7, 2024
- Minor Enrollment target: 32 to 29
- Primary completion date: Jun 30, 2024 to Dec 31, 2023
- Start date: Jun 20, 2023 to Jun 12, 2023
- Interventions: 100mg bid dose of hydroxychloroquine combined with three predefined dose groups of palbociclib (Drug), RP2D dose of 100mg bid of… to 600mg bid dose of hydroxychloroquine combined with three predefined dose groups of palbociclib (Drug), RP2D dose of 600mg bid of…
- Study First Submitted
- Notable: the plan changed
- Minor: routine updates
Endpoints
Primary
Secondary (2)
Arms and interventions
600mg bid dose of hydroxychloroquine group combined with three predefined dose groups of palbociclib: 100mg QD, 150mg QD, and 200mg QD, separately.
After MTD was determined, RP2D dose was selected for phase II clinical trial.
Drugs: 600mg bid dose of hydroxychloroquine combined with three predefined dose groups of palbociclib, RP2D dose of 600mg bid of hydroxychloroquine combined with palbociclib was selected for phase II clinical trial.
Sites
1 site in 1 country
- Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityGuangzhou, Guangdong, China